Skip to main content

Table 3 Noncompartmental pharmacokinetic parameters for AS1402 after i.v. administration (mean ± SD)

From: Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer

Dose cohort

1 mg/kg

(n = 3)

3 mg/kg

(n = 9)

9 mg/kg

(n = 6)

16 mg/kg

(n = 8)

Cmax

(μg/ml)

21.1 ± 4.67

73.5 ± 11.8

209 ± 17.3

514 ± 232

Half-life (h)

147 ± 19.3

128 ± 50.6

111 ± 23.0

102 ± 22.6

AUC0-∞(μg*h/ml)

2,399 ± 1,205

9,032 ± 3,314

24,757 ± 3,625

49,302 ± 10,971

CL (ml/h/kg)

0.486 ± 0.213

0.386 ± 0.174

0.369 ± 0.0488

0.337 ± 0.0648

Vss (ml/kg)

68.2 ± 16.9

54.6 ± 12.2

56.8 ± 7.14

50.3 ± 18.56

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us